Genetic markers associated with progression in early mycosis fungoides

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 11, 2014, Pages 1431-1435

  Johnson, V E ^a   Vonderheid, E C ^b   Hess, A D ^b   Eischen, C M ^a   McGirt, L Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; MIC B PROTEIN; PLS3 PROTEIN; PROTEIN; RNA; STAT4 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; DISEASE COURSE; EARLY CANCER; FEMALE; FOLLOW UP; GENETIC MARKER; HUMAN; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RNA EXTRACTION; SKIN BIOPSY;

EID: 85006335435     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12299     Document Type: Article

References (28)

1. Rappaport H, Thomas LB. Mycosis fungoides: the pathology of extracutaneous involvement. Cancer 1974; 34: 1198–1229.
2. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999; 40(6 Pt 1): 914–924.
3. Talpur R, Singh L, Daulat S et al. Long-term outcomes of 1263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051–5060.
4. Bernengo MG, Quaglino P, Novelli M et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998; 9: 857–863.
5. Papadavid E, Economidou J, Psarra A et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol 2003; 148: 709–718.
6. Chong BF, Wilson AJ, Gibson HM et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008; 14: 646–653.
7. Gjerdrum LM, Woetmann A, Odum N et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21: 2512–2518.
8. Klemke CD, Fritzsching B, Franz B et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123–1129.
9. Wada DA, Wilcox RA, Weenig RH, Gibson LE. Paucity of intraepidermal FoxP3-positive T cells in cutaneous T-cell lymphoma in contrast with spongiotic and lichenoid dermatitis. J Cutan Pathol 2010; 37: 535–541.
10. Hallermann C, Niermann C, Schulze HJ. Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides. Eur J Haematol 2007; 78: 260–263.
11. Valencak J, Schmid K, Trautinger F et al. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas. J Dermatol Sci 2011; 64: 185–190.
12. Maj J, Jankowska-Konsur A, Sadakierska-Chudy A et al. Altered microRNA expression in mycosis fungoides. Br J Dermatol 2012; 166: 331–336.
13. Litvinov IV, Jones DA, Sasseville D et al. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res: an official journal of the American Association for Cancer Research 2010; 16: 2106–2114.
14. Vonderheid EC, Pavlov I, Delgado JC et al. Prognostic factors and risk stratification early mycosis fungoides. Leuk Lymphoma 2013; May 7. [Epub ahead of print]
15. Capriotti E, Vonderheid EC, Thoburn CJ, Wasik MA, Bahler DW, Hess AD. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008; 49: 1190–1201.
16. Tracey L, Villuendas R, Dotor AM et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003; 102: 1042–1050.
17. Krejsgaard T, Odum N, Geisler C et al. Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2012; 26: 424–432.
18. Nebozhyn M, Loboda A, Kari L et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006; 107: 3189–3196.
19. Nielsen M, Kaltoft K, Nordahl M et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A 1997; 94: 6764–6769.
20. Showe LC, Fox FE, Williams D, Au K, Niu Z, Rook AH. Depressed IL-12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J Immunol 1999; 163: 4073–4079.
21. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004; 8: 409–422.
22. Szabo SJ, Jacobson NG, Dighe AS, Gubler U, Murphy KM. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995; 2: 665–675.
23. Nishikomori R, Usui T, Wu CY, Morinobu A, O'Shea JJ, Strober W. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol 2002; 169: 4388–4398.
24. Murphy KM, Ouyang W, Szabo SJ et al. T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr Top Microbiol Immunol 1999; 238: 13–26.
25. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–173.
26. Savvateeva MV, Savina MI, Markusheva LI, Samsonov VA. Relative content of cytokines in different tissues in mycosis fungoides. Bull Exp Biol Med 2002; 134: 175–176.
27. Pawlaczyk M, Sobieska M. A correlation between acute phase proteins and cytokines in patients suffering from mycosis fungoides. Acta Dermatovenerol Alp Panonica Adriat 2006; 15: 107–112.
28. Sun G, Berthelot C, Li Y et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 2009; 60: 231–235.